Question 1

Does Royce & Associates own AXSM stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Royce & Associates holds 91,041 shares of AXSM (Axsome Therapeutics), worth $22.3M.

Question 2

How many shares of AXSM does Royce & Associates own?

Accepted Answer

As of its Q2 2026 13F, Royce & Associates holds 91,041 shares of AXSM (Axsome Therapeutics).

Question 3

What is Royce & Associates' AXSM position worth?

Accepted Answer

As of its Q2 2026 13F, Royce & Associates' AXSM position is worth $22.3M.

Question 4

Is Royce & Associates buying or selling AXSM?

Accepted Answer

In Q2 2026, Royce & Associates reduced its AXSM position by 2,976 shares (-3.2%).

Question 5

When did Royce & Associates first buy AXSM?

Accepted Answer

Royce & Associates already held AXSM in its Q1 2019 13F, the earliest on record, and has listed it in 20 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	91,041	-3.2%	$22.3M	0.2%	$244.77	0
2026-Q1	Unchanged	94,017	0.0%	$15.9M	0.2%	$169.02	0
2025-Q4	Increased	94,017	+67.8%	$17.2M	0.2%	$182.64	50
2025-Q3	Increased	56,036	+117.6%	$6.8M	0.1%	$121.45	44
2025-Q2	Decreased	25,757	-14.9%	$2.7M	0.0%	$104.39	0
2025-Q1	Decreased	30,257	-18.2%	$3.5M	0.0%	$116.63	0
2024-Q4	Increased	37,000	+64.4%	$3.1M	0.0%	$84.61	39
2024-Q3	Increased	22,500	+73.1%	$2M	0.0%	$89.87	39